CytomX Therapeutics (CTMX) Stock Overview
Operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CTMX Community Fair Values
Create NarrativeSee what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CytomX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$8.21 |
| 52 Week Low | US$1.90 |
| Beta | 2.14 |
| 1 Month Change | 1.23% |
| 3 Month Change | -11.11% |
| 1 Year Change | 64.00% |
| 3 Year Change | 126.21% |
| 5 Year Change | -35.31% |
| Change since IPO | -74.57% |
Recent News & Updates
Seeking Alpha • Aug 12
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
Summary CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX’s pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through 1H2027. Regeneron has also expanded its collaboration with CTMX, which bodes well for the PROBODY platform and gives some additional nondilutive funding as well. Thus, I believe CTMX is now a much more compelling play in this sector, which is why I upgrade the stock to a speculative “Buy” at these levels. Read the full article on Seeking Alpha
New Narrative • Aug 08
Late-Stage Oncology Setbacks Will Test This ADC Pipeline Before Longer-Term Promise Emerges
Catalysts About CytomX Therapeutics CytomX Therapeutics develops antibody drug conjugates and masked biologics that aim to target solid tumors while limiting systemic toxicity. What are the underlying business or industry changes driving this perspective?Recent updates
Seeking Alpha • Aug 12
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
Summary CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX’s pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through 1H2027. Regeneron has also expanded its collaboration with CTMX, which bodes well for the PROBODY platform and gives some additional nondilutive funding as well. Thus, I believe CTMX is now a much more compelling play in this sector, which is why I upgrade the stock to a speculative “Buy” at these levels. Read the full article on Seeking AlphaNew Narrative • Aug 08
Late-Stage Oncology Setbacks Will Test This ADC Pipeline Before Longer-Term Promise Emerges
Catalysts About CytomX Therapeutics CytomX Therapeutics develops antibody drug conjugates and masked biologics that aim to target solid tumors while limiting systemic toxicity. What are the underlying business or industry changes driving this perspective?
Narrative Update • Jun 25
CTMX: De Risked Epithelial Program And Pullback Will Support Future Repricing
CytomX Therapeutics' analyst fair value estimate has shifted from $10.00 to $16.00, with analysts pointing to its de risked epithelial cell adhesion molecule antibody drug conjugate, the ability to manage toxicity risks, and the recent pullback in the stock as key reasons for the updated view. Analyst Commentary Recent research coverage on CytomX Therapeutics highlights growing interest in the company’s epithelial cell adhesion molecule antibody drug conjugate program.
Narrative Update • Jun 11
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Analysts have nudged their average price target for CytomX Therapeutics higher into the mid teens, citing stronger conviction in the late line colorectal cancer potential of varsetatug masetecan and CX-2051 following Phase 1 expansion data and a series of recent target increases that include moves to $11, $12 and $17. Analyst Commentary Recent research updates on CytomX Therapeutics cluster around two themes, the commercial potential of varsetatug masetecan and CX-2051 in colorectal and colon cancer, and how much risk is acceptable at current valuation levels.Narrative Update • May 28
CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects
Analysts have trimmed their average price target for CytomX Therapeutics by about $1.22, citing updated expectations for revenue growth, profitability and future P/E. They still point to supportive recent research that highlights the potential of Varseta-M and CX-2051 in colorectal cancer.Analysis Article • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...Analysis Article • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...Narrative Update • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.Narrative Update • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.Narrative Update • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Narrative Update • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.Narrative Update • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.Narrative Update • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.Analysis Article • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...Narrative Update • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.Narrative Update • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.Narrative Update • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.Narrative Update • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.Narrative Update • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.Analysis Article • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...Narrative Update • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.Narrative Update • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.Analysis Article • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analysis Article • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...Narrative Update • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.Analysis Article • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analysis Article • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...Analysis Article • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
New Narrative • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.Analysis Article • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...Analysis Article • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Shareholder Returns
| CTMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | 6.3% | -1.2% |
| 1Y | 64.0% | 47.2% | 18.3% |
Return vs Industry: CTMX exceeded the US Biotechs industry which returned 47.2% over the past year.
Return vs Market: CTMX exceeded the US Market which returned 18.3% over the past year.
Price Volatility
| CTMX volatility | |
|---|---|
| CTMX Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTMX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CTMX's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 69 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
CytomX Therapeutics, Inc. Fundamentals Summary
| CTMX fundamental statistics | |
|---|---|
| Market cap | US$714.71m |
| Earnings (TTM) | -US$82.65m |
| Revenue (TTM) | US$18.30m |
39.0x
P/S Ratio-8.6x
P/E RatioIs CTMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTMX income statement (TTM) | |
|---|---|
| Revenue | US$18.30m |
| Cost of Revenue | US$0 |
| Gross Profit | US$18.30m |
| Other Expenses | US$100.96m |
| Earnings | -US$82.65m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 100.00% |
| Net Profit Margin | -451.59% |
| Debt/Equity Ratio | 0% |
How did CTMX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/24 19:30 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CytomX Therapeutics, Inc. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |